July 10, 2019 07:21 AM EDTUpdated 04:08 PM

Opening new battlefront with Gilead, GSK touts new Dovato non-inferiority data months after first approval

GlaxoSmithKline is giving its best shot at rivaling Gilead on its home turf with Dovato, a 2-drug HIV regimen approved in Europe just days …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Open­ing new bat­tle­front with Gilead, GSK touts new Dova­to non-in­fe­ri­or­i­ty da­ta months af­ter first ap­proval